FDA clears Philips imaging solutions for management of cardiac, lung complications related to COVID-19
Royal Philips announced Wednesday, May 13, that its ultrasound imaging solutions have been cleared by the FDA for the management of cardiac and lung complications associated with COVID-19.
This clearance—a first for the industry, according to Philips—allows the company to assist healthcare providers diagnose and treat COVID-19 patients with its full ultrasound product line.
“Many healthcare providers have told us that our handheld and portable ultrasound solutions are playing a valuable role in their efforts to combat COVID-19,” Bich Le, senior vice president and general manager of Ultrasound at Philips, said in a statement. “With this regulatory clearance we can offer clear guidance to ensure safe and effective use of ultrasound to manage COVID-19-related lung and cardiac complications. At the same time, we are investing significantly to ramp up production globally, including at our ultrasound manufacturing plants in the U.S.”
Philips has also created a detailed guidance to help its customers assess COVID-19-related complications with its ultrasound solutions. That guidance, and other key information, is available here.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.